Xencor Inc. (Nasdaq: XNCR)

https://www.xencor.com

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. Currently, 12 candidates engineered with Xencor’s XmAb® technology are in clinical development internally and with partners. Xencor’s internal programs include: XmAb®5871 in Phase 2 development for the treatment of IgG4-Related Disease, and also for the treatment of Systemic Lupus Erythematosus; XmAb®7195 in Phase 1 development for the treatment of asthma and allergic diseases; XmAb®14045 in Phase 1 development for acute myeloid leukemia; XmAb®13676 in Phase 1 development for B-cell malignancies; XmAb®18087 in Phase 1 development for the treatment of neuroendocrine tumors; and XmAb®20717, XmAb®22841 and XmAb®23104 in pre-clinical development for the treatment of multiple cancers. Xencor’s XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Novartis, Amgen, MorphoSys, Merck, CSL/Janssen, Alexion and Boehringer Ingelheim. *

	Start	1997-01-01 established
	Industry	therapeutic antibody
	Industry 2	XmAb™ technology (Xencor)
	Person	Dahiyat, Bassil (Xencor 200607 President + CEO)
	Person 2	Baracchini, Edgardo (Xencor 201802 CBO)

	Street	111 West Lemon Avenue
	City	91016 Monrovia, CA
	Tel	+1-626-305-5900
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2023-07-10